Return to Today's science sparks archives

2014-10-01

Fig 3. Kaplan-Meier 10-year breast cancer-specific survival analyses in the molecular taxonomy of breast cancer international consortium dataset (all patients). B) Based on intrinsic subtype and cHER2 status.

Fig 3. Kaplan-Meier 10-year breast cancer-specific survival analyses in the molecular taxonomy of breast cancer international consortium dataset (all patients). B) Based on intrinsic subtype and cHER2 status.
  • Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J

  • J Natl Cancer Inst. 2014 Aug 19;106(8). pii: dju152.

2014-10-02

Fig 1. (A) Disease-free survival (DFS) of all patients undergoing R0 resection (n = 115).

Fig 1. (A) Disease-free survival (DFS) of all patients undergoing R0 resection (n = 115).
  • Butte JM, Kingham TP, Gönen M, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR

  • J Am Coll Surg. 2014 Sep;219(3):416-29

2014-10-03

Fig 1. Representative case (patient 4) of salt-and-pepper retinopathy after intravitreal melphalan.

Fig 1. Representative case (patient 4) of salt-and-pepper retinopathy after intravitreal melphalan.
  • Francis JH, Schaiquevich P, Buitrago E, Del Sole MJ, Zapata G, Croxatto JO, Marr BP, Brodie SE, Berra A, Chantada GL, Abramson DH

  • Ophthalmology. 2014 Sep;121(9):1810-7.

2014-10-06

Fig B. The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. CT images of the index patient before surgery of the recurrent tumor, before combined AZD7762 and irinotecan therapy, and 1 month after combined treatment (left, middle, and right, respectively).

Fig B. The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. CT images of the index patient before surgery of the recurrent tumor, before combined AZD7762 and irinotecan therapy, and 1 month after combined treatment (left, middle, and right, respectively).
  • Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, Socci ND, Viale A, Schwartz GK, Reuter V, Bochner BH, Rosenberg JE, Bajorin DF, Berger MF, Petrini JH, Solit DB, Taylor BS

  • Cancer Discov. 2014 Sep;4(9):1014-21
Open Access button

2014-10-07

Fig 2. DGK-α is required for MTOC polarization in TCR photoactivation experiments.

Fig 2. DGK-α is required for MTOC polarization in TCR photoactivation experiments.
  • Chauveau A, Le Floc'h A, Bantilan NS, Koretzky GA, Huse M

  • Sci Signal. 2014 Aug 26;7(340):ra82

2014-10-08

Fig 1. Kaplan–Meier probability curves for RFS after reflex FISH stratified by FISH result. Differences in RFS are statistically significant (P < 0.001, log-rank test).

Fig 1. Kaplan–Meier probability curves for RFS after reflex FISH stratified by FISH result. Differences in RFS are statistically significant (P < 0.001, log-rank test).
  • Kim PH, Sukhu R, Cordon BH, Sfakianos JP, Sjoberg DD, Hakimi AA, Dalbagni G, Lin O, Herr HW.

  • BJU Int. 2014 Sep;114(3):354-9

2014-10-10

Fig 2B. There was no difference in disease-free survival in patients who were MRD-negative after the completion of consolidation therapy, regardless of whether they received an additional 1 year of maintenance therapy with ATRA, methotrexate (MTX), and 6-mercaptopurine (6-MP) or were observed.

Fig 2B. There was no difference in disease-free survival in patients who were MRD-negative after the completion of consolidation therapy, regardless of whether they received an additional 1 year of maintenance therapy with ATRA, methotrexate (MTX), and 6-mercaptopurine (6-MP) or were observed.
  • Watts JM, Tallman MS

  • Blood Rev. 2014 Sep;28(5):205-212.

2014-10-13

Fig 1. A LigD-LIG-independent NHEJ pathway participates in chromosomal repair. (B) Fraction survival of wild-type (wt), ligD-(K484A), and ΔligD strains was plotted in log scale with the IR dose on the x axis.

Fig 1. A LigD-LIG-independent NHEJ pathway participates in chromosomal repair. (B) Fraction survival of wild-type (wt), ligD-(K484A), and ΔligD strains was plotted in log scale with the IR dose on the x axis.
  • Bhattarai H, Gupta R, Glickman MS

  • J Bacteriol. 2014 Oct 1;196(19):3366-76.

2014-10-14

Fig 1. Diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH). This tumorlet from a patient with DIPNECH consists of nodular clusters of neuroendocrine cells in a peribronchiolar location, causing compression of the bronchiolar lumen (Hematoxylin and eosin ×20).

Fig 1. Diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH). This tumorlet from a patient with DIPNECH consists of nodular clusters of neuroendocrine cells in a peribronchiolar location, causing compression of the bronchiolar lumen (Hematoxylin and eosin ×20).
  • Travis WD

  • Thorac Surg Clin. 2014 Aug;24(3):257-66

2014-10-15

Fig 1. Estrogen receptor (ER)–positive and ER-negative breast cancers are fundamentally different diseases.

Fig 1. Estrogen receptor (ER)–positive and ER-negative breast cancers are fundamentally different diseases.
  • Weigelt B, Reis-Filho JS

  • J Natl Cancer Inst. 2014 Aug 12;106(8). pii: dju211.

2014-10-16

Fig 1. Human prostate cancer tumor harvesting and flow cytometry plot illustrating specific populations from a human prostate cancer. (A) Tumor nodules are harvested to generate a cell suspension. Tumor content of the processed sample is confirmed using conventional Hematoxylin and Eosin staining. (B) Cells staining positively for DAPI are excluded to isolate only viable cells.

Fig 1. Human prostate cancer tumor harvesting and flow cytometry plot illustrating specific populations from a human prostate cancer. (A) Tumor nodules are harvested to generate a cell suspension. Tumor content of the processed sample is confirmed using conventional Hematoxylin and Eosin staining. (B) Cells staining positively for DAPI are excluded to isolate only viable cells.
  • Vidal SJ, Quinn SA, de la Iglesia-Vicente J, Bonal DM, Rodriguez-Bravo V, Firpo-Betancourt A, Cordon-Cardo C, Domingo-Domenech J.

  • J Vis Exp. 2014 Mar 14;(85)

2014-10-17

Fig 3. Kaplan–Meier curve showing PFS in patients who received the concurrent regimen of afatinib and cetuximab.

Fig 3. Kaplan–Meier curve showing PFS in patients who received the concurrent regimen of afatinib and cetuximab.
  • Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W

  • Cancer Discov. 2014 Sep;4(9):1036-45.

2014-10-20

Fig 5. Histiocytic sarcomas and soft tissue sarcomas from mice with Ptprd and Cdkn2a deletion.

Fig 5. Histiocytic sarcomas and soft tissue sarcomas from mice with Ptprd and Cdkn2a deletion.
  • Ortiz B, White JR, Wu WH, Chan TA

  • Oncotarget. 2014 Aug 30;5(16):6976-82.
Open Access button

2014-10-21

Fig 4b. SCCRO5 overexpression is common in human tumors and correlates with outcomes. Western blot analysis showing SCCRO5 protein expression in representative head and neck and lung SCCs (T) and matched normal (N) samples.

Fig 4b. SCCRO5 overexpression is common in human tumors and correlates with outcomes. Western blot analysis showing SCCRO5 protein expression in representative head and neck and lung SCCs (T) and matched normal (N) samples.
  • Bommeljé CC, Weeda VB, Huang G, Shah K, Bains S, Buss E, Shaha M, Gönen M, Ghossein R, Ramanathan SY, Singh B

  • Clin Cancer Res. 2014 Jan 15;20(2):372-81.
Open Access button

2014-10-22

Fig 4a. Whole genome analysis of mutational concordance. Concordant and discordant non-synonymous mutations and indels for four CRC patients.

Fig 4a. Whole genome analysis of mutational concordance. Concordant and discordant non-synonymous mutations and indels for four CRC patients.
  • Brannon A, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D Angelica MI, Weiser MR, Solit DB, Berger MF

  • Genome Biol. 2014 Aug 28;15(8):454.
Open Access button

2014-10-23

Fig 1. CD8+ and DC-Lamp+ cell densities are heterogeneous in non-small cell carcinoma.

Fig 1. CD8+ and DC-Lamp+ cell densities are heterogeneous in non-small cell carcinoma.
  • Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, Goc J, Biton J, Ouakrim H, Cremer I, Dieu-Nosjean MC, Damotte D

  • PLoS One. 2014 Sep 19;9(9):e106914.
Open Access button

2014-10-24

Fig 1. Cumulative incidence of death by smoking status (left) and pack-years among smokers (right).

Fig 1. Cumulative incidence of death by smoking status (left) and pack-years among smokers (right).
  • Ehdaie B, Furberg H, Zabor EC, Hakimi AA, Russo P

  • J Urol. 2014 Mar;191(3):597-602.
Open Access button

2014-10-27

Figure 1A and 1B. 


Fundus Photograph of Case 1. A, Vitreous seed tethered to the injection site following 2 intravitreal melphalan injections B, One year later, following cryotherapy and 3 additional injections, the vitreous seed has regressed to a collection of pigment.

Figure 1A and 1B. Fundus Photograph of Case 1. A, Vitreous seed tethered to the injection site following 2 intravitreal melphalan injections B, One year later, following cryotherapy and 3 additional injections, the vitreous seed has regressed to a collection of pigment.
  • Francis JH, Marr BP, Brodie SE, Gobin YP, Abramson DH

  • JAMA Ophthalmol. 2014 Aug;132(8):1024-5

2014-10-28

Fig 2. Cumulative incidence curve for local recurrence by radiation treatment group. C-EBRT, conventional external-beam radiation therapy; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; M, multivariable; U, univariable.

Fig 2. Cumulative incidence curve for local recurrence by radiation treatment group. C-EBRT, conventional external-beam radiation therapy; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; M, multivariable; U, univariable.
  • Folkert MR, Singer S, Brennan MF, Kuk D, Qin LX, Kobayashi WK, Crago AM, Alektiar KM

  • J Clin Oncol. 2014 Oct 10;32(29):3236-41.

2014-10-29

Fig 3. General model of palliative care services integrated into oncology practice. MA, medical assistant; RN, registered nurse.

Fig 3. General model of palliative care services integrated into oncology practice. MA, medical assistant; RN, registered nurse.
  • Partridge AH, Seah DS, King T, Leighl NB, Hauke R, Wollins DS, Von Roenn JH

  • J Clin Oncol. 2014 Oct 10;32(29):3330-6.

2014-10-30

Fig 2. Example of a case (case 1). A, Hematoxylin-eosin. B, Immunostain for podoplanin/D2-40. C, Immunostain for CD31. D, Immunostain for CD68 (original magnifications ×100).

Fig 2. Example of a case (case 1). A, Hematoxylin-eosin. B, Immunostain for podoplanin/D2-40. C, Immunostain for CD31. D, Immunostain for CD68 (original magnifications ×100).
  • Gui X1, Zhou Y, Eidus L, Falck V, Gao ZH, Qin L

  • Arch Pathol Lab Med. 2014 Aug;138(8):1059-66

2014-10-31

Graphical abstract.

Graphical abstract.
  • Gao P, Zillinger T, Wang W, Ascano M, Dai P, Hartmann G, Tuschl T, Deng L3, Barchet W, Patel DJ

  • Cell Rep. 2014 Sep 25;8(6):1668-76.
Open Access button

2014-11-03

Fig 2. Fracture-free survival by type of urinary diversion in patients who received cystectomy.

Fig 2. Fracture-free survival by type of urinary diversion in patients who received cystectomy.
  • Gupta A, Atoria CL, Ehdaie B, Shariat SF, Rabbani F, Herr HW, Bochner BH, Elkin EB

  • J Clin Oncol. 2014 Oct 10;32(29):3291-8.

2014-11-04

Fig 1. Cumulative incidence of subsequent malignant neoplasms after retinoblastoma by treatment received. (A) Bone tumor.

Fig 1. Cumulative incidence of subsequent malignant neoplasms after retinoblastoma by treatment received. (A) Bone tumor.
  • Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN, Kleinerman RA

  • J Clin Oncol. 2014 Oct 10;32(29):3284-90.

2014-11-05

Fig 2. 3-arm and 4-arm constructs can be radiolabeled in 1 step at 37°C. (B) Time course of labeling at different temperatures.

Fig 2. 3-arm and 4-arm constructs can be radiolabeled in 1 step at 37°C. (B) Time course of labeling at different temperatures.
  • Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA

  • J Nucl Med. 2014 Sep;55(9):1492-8.

2014-11-06

Fig 1. CONSORT diagram for GOG (Gynecologic Oncology Group) 0199, the National Ovarian Cancer Prevention and Early Detection Study. ROCA, risk of ovarian cancer algorithm; RRSO, risk-reducing salpingo-oophorectomy.

Fig 1. CONSORT diagram for GOG (Gynecologic Oncology Group) 0199, the National Ovarian Cancer Prevention and Early Detection Study. ROCA, risk of ovarian cancer algorithm; RRSO, risk-reducing salpingo-oophorectomy.
  • Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH

  • J Clin Oncol. 2014 Oct 10;32(29):3275-83.

2014-11-07

Fig 4. Representative coronal PET images (Maximum Intensity Projection) of SCID mice bearing SK-BR-3 xenografts on the right shoulder. Images A, B and C are the results of 15-min static scans following iv injection of the mouse with [18F]-18. Images A, B and C were obtained at 30, 60 and 240 min after injection, respectively.

Fig 4. Representative coronal PET images (Maximum Intensity Projection) of SCID mice bearing SK-BR-3 xenografts on the right shoulder. Images A, B and C are the results of 15-min static scans following iv injection of the mouse with [18F]-18. Images A, B and C were obtained at 30, 60 and 240 min after injection, respectively.
  • Daumar P, Zeglis BM, Ramos N, Divilov V, Sevak KK, Pillarsetty N, Lewis JS

  • Eur J Med Chem. 2014 Oct 30;86:769-81.

2014-11-10

Fig 3. Tumor MRE11 status is significantly prognostic for DFS and OS.

(A) Disease free survival for dMRE11 (n = 70; events = 24); 5-yr rate: 67% (95% CI: 56–79%) vs. pMRE11 (n = 555; events = 240); 5-yr rate: 59% (95% CI: 55–63%). (B) Overall survival for dMRE11 (n = = 70; events = 23); 5-yr rate: 68% (95% CI: 58–80%) vs. pMRE11 (n = 555; events = 194); 5-yr rate: 71% (95% CI: 67–75%).

Fig 3. Tumor MRE11 status is significantly prognostic for DFS and OS. (A) Disease free survival for dMRE11 (n = 70; events = 24); 5-yr rate: 67% (95% CI: 56–79%) vs. pMRE11 (n = 555; events = 240); 5-yr rate: 59% (95% CI: 55–63%). (B) Overall survival for dMRE11 (n = = 70; events = 23); 5-yr rate: 68% (95% CI: 58–80%) vs. pMRE11 (n = 555; events = 194); 5-yr rate: 71% (95% CI: 67–75%).
  • Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ Jr, Maizels N

  • PLoS One. 2014 Oct 13;9(10):e108483
Open Access button

2014-11-11

Fig 4. Socioeconomic Characteristics Of Communities Served By Hospital-Affiliated Clinics In Comparison To Characteristics Of Communities Served By Disproportionate-Share Hospitals, By Time Of Registration For The 340B Program

Fig 4. Socioeconomic Characteristics Of Communities Served By Hospital-Affiliated Clinics In Comparison To Characteristics Of Communities Served By Disproportionate-Share Hospitals, By Time Of Registration For The 340B Program
  • Conti RM, Bach PB

  • Health Aff (Millwood). 2014 Oct 1;33(10):1786-92

2014-11-12

Fig 1. Molecular mechanism of androgen receptor (AR) signaling in castrate-resistant prostate cancer.

Fig 1. Molecular mechanism of androgen receptor (AR) signaling in castrate-resistant prostate cancer.
  • Carver BS

  • Drug Discov Today. 2014 Sep;19(9):1493-7.

2014-11-13

Figure 3. Quality of Life Mean Scores of the EORTC QLQ-C30 by levels of Fatigue and Haemoglobin. The upper panel reports mean scores of the global health status/quality of life (QoL) scale of the EORTC QLQ-C30 by levels of fatigue, defined by quartiles of the FACIT Fatigue scale distribution. . The lower panel reports mean scores of the global health status/QoL scale of the EORTC QLQ-C30 by levels of haemoglobin (Hb) values (g/l), defined by quartiles of Hb distribution.

Figure 3. Quality of Life Mean Scores of the EORTC QLQ-C30 by levels of Fatigue and Haemoglobin. The upper panel reports mean scores of the global health status/quality of life (QoL) scale of the EORTC QLQ-C30 by levels of fatigue, defined by quartiles of the FACIT Fatigue scale distribution. . The lower panel reports mean scores of the global health status/QoL scale of the EORTC QLQ-C30 by levels of haemoglobin (Hb) values (g/l), defined by quartiles of Hb distribution.
  • Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F

  • Br J Haematol. 2014 Oct 1

2014-11-14

Graphical abstract: Here, we show that a dedicated Foxp3 intronic element CNS2 maintains Treg cell lineage identity by acting as a sensor of the essential Treg cell growth factor IL-2 and its downstream target STAT5. CNS2 sustains Foxp3 expression during division of mature Treg cells when IL-2 is limiting and counteracts proinflammatory cytokine signaling that leads to the loss of Foxp3. CNS2-mediated stable inheritance of Foxp3 expression is critical for adequate suppression of diverse types of chronic inflammation by Treg cells and prevents their differentiation into inflammatory effector cells. The described mechanism may represent a general principle of the inheritance of differentiated cell states.

Graphical abstract: Here, we show that a dedicated Foxp3 intronic element CNS2 maintains Treg cell lineage identity by acting as a sensor of the essential Treg cell growth factor IL-2 and its downstream target STAT5. CNS2 sustains Foxp3 expression during division of mature Treg cells when IL-2 is limiting and counteracts proinflammatory cytokine signaling that leads to the loss of Foxp3. CNS2-mediated stable inheritance of Foxp3 expression is critical for adequate suppression of diverse types of chronic inflammation by Treg cells and prevents their differentiation into inflammatory effector cells. The described mechanism may represent a general principle of the inheritance of differentiated cell states.
  • Feng Y, Arvey A, Chinen T, van der Veeken J, Gasteiger G, Rudensky AY

  • Cell. 2014 Aug 14;158(4):749-63.
Open Access button

2014-11-17

Graphical abstract: To ensure that DNA replication during meiosis is followed by recombination events, a kinase that can promote the formation of double-strand breaks is recruited to the replisome. Consequently, the DNA breaks that initiate recombination are primed to form in the wake of the replication fork.

Graphical abstract: To ensure that DNA replication during meiosis is followed by recombination events, a kinase that can promote the formation of double-strand breaks is recruited to the replisome. Consequently, the DNA breaks that initiate recombination are primed to form in the wake of the replication fork.
  • Murakami H, Keeney S

  • Cell. 2014 Aug 14;158(4):861-73
Open Access button

2014-11-18

Fig 1. Nanoparticle quenching of Cerenkov luminescence.

Fig 1. Nanoparticle quenching of Cerenkov luminescence.
  • Thorek DL, Das S, Grimm J.

  • Small. 2014 Sep 24;10(18):3729-34

2014-11-19

Fig 1. MyD88-dependent fucosylation of small intestine IECs by systemic stimulation of TLRs.

Fig 1. MyD88-dependent fucosylation of small intestine IECs by systemic stimulation of TLRs.
  • Pickard JM, Maurice CF, Kinnebrew MA, Abt MC, Schenten D, Golovkina TV, Bogatyrev SR, Ismagilov RF, Pamer EG, Turnbaugh PJ, Chervonsky AV

  • Nature. 2014 Oct 30;514(7524):638-41

2014-11-20

Fig 1B. Cartoon renderings (see Materials and Methods; unprocessed images are shown in supplementary material Fig. S2) of typical aggregate morphologies on day 5 following the conditions shown in A; images are not to scale. Maximum elongation was observed following pulsed treatment within the day 2-3 time frame (P3).

Fig 1B. Cartoon renderings (see Materials and Methods; unprocessed images are shown in supplementary material Fig. S2) of typical aggregate morphologies on day 5 following the conditions shown in A; images are not to scale. Maximum elongation was observed following pulsed treatment within the day 2-3 time frame (P3).
  • van den Brink SC, Baillie-Johnson P, Balayo T, Hadjantonakis AK, Nowotschin S, Turner DA, Martinez Arias A

  • Development. 2014 Nov;141(22):4231-42
Open Access button

2014-11-21

Fig 4. Virus protein ICP6 interacts with RIP3 through the RHIM domains of both proteins and is required for HSV-1–induced necrosis. (A) RIP3 KO MEFs expressing WT RIP3 (RIP3 was double tagged with Flag and HA) infected with HSV-1 (MOI = 2) for 5 h. Cell lysates were collected and immunoprecipitated with anti-Flag and anti-HA agarose beads as described in Materials and Methods. The eluted RIP3-associated complexes were subjected to SDS/PAGE and detected by silver staining. The indicated bands were excised and then digested and analyzed by mass spectrometry.

Fig 4. Virus protein ICP6 interacts with RIP3 through the RHIM domains of both proteins and is required for HSV-1–induced necrosis. (A) RIP3 KO MEFs expressing WT RIP3 (RIP3 was double tagged with Flag and HA) infected with HSV-1 (MOI = 2) for 5 h. Cell lysates were collected and immunoprecipitated with anti-Flag and anti-HA agarose beads as described in Materials and Methods. The eluted RIP3-associated complexes were subjected to SDS/PAGE and detected by silver staining. The indicated bands were excised and then digested and analyzed by mass spectrometry.
  • Wang X, Li Y, Liu S, Yu X, Li L, Shi C, He W, Li J, Xu L, Hu Z, Yu L, Yang Z, Chen Q, Ge L, Zhang Z, Zhou B, Jiang X, Chen S, He S.

  • Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15438-43

2014-11-24

Fig 2. (L) Immunofluorescence staining of spleen sections showing DsRed-MLL-AF9 cells, CD45-expressing (green) cells, and 4,6-diamidino-2-phenylindole nuclei staining (blue). Left panel (×10); right small panels (×63).

Fig 2. (L) Immunofluorescence staining of spleen sections showing DsRed-MLL-AF9 cells, CD45-expressing (green) cells, and 4,6-diamidino-2-phenylindole nuclei staining (blue). Left panel (×10); right small panels (×63).
  • Krevvata M, Silva BC, Manavalan JS, Galan-Diez M, Kode A, Matthews BG, Park D, Zhang CA, Galili N, Nickolas TL, Dempster DW, Dougall W, Teruya-Feldstein J, Economides AN, Kalajzic I, Raza A, Berman E, Mukherjee S, Bhagat G, Kousteni S

  • Blood. 2014 Oct 30;124(18):2834-46

2014-11-25

Fig 1. Study treatment schema and comparison with the European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada (EORTC/NCIC) standard glioblastoma regimen (1). BEV, bevacizumab; RT, radiotherapy; TMZ, temozolomide.

Fig 1. Study treatment schema and comparison with the European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada (EORTC/NCIC) standard glioblastoma regimen (1). BEV, bevacizumab; RT, radiotherapy; TMZ, temozolomide.
  • Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT

  • Clin Cancer Res. 2014 Oct 1;20(19):5023-31.

2014-11-26

Fig 3. Waterfall plot of best tumour response. Response was measured as the largest post-baseline percentage reduction in the sum of longest diameters of target lesions for all assessable patients with a radiographic post-baseline assessment (n=42).

Fig 3. Waterfall plot of best tumour response. Response was measured as the largest post-baseline percentage reduction in the sum of longest diameters of target lesions for all assessable patients with a radiographic post-baseline assessment (n=42).
  • Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH

  • Lancet Oncol. 2014 Sep;15(10):1119-28.

2014-11-28

Fig 1. Independent-samples t-tests of group differences between men classified into “low” vs. “high” sexual bother groups.

Fig 1. Independent-samples t-tests of group differences between men classified into “low” vs. “high” sexual bother groups.
  • Benedict C, Traeger L, Dahn JR, Antoni M, Zhou ES, Bustillo N, Penedo FJ

  • J Sex Med. 2014 Oct;11(10):2571-80.

2014-12-01

Fig 1. An intestinal-type ampullary adenocarcinoma showing a cribriform architectural pattern (A) and nuclear hyperchromasia and pseudostratification (B) on H&E.

Fig 1. An intestinal-type ampullary adenocarcinoma showing a cribriform architectural pattern (A) and nuclear hyperchromasia and pseudostratification (B) on H&E.
  • Ang DC, Shia J, Tang LH, Katabi N, Klimstra DS

  • Am J Surg Pathol. 2014 Oct;38(10):1371-9.

2014-12-02

Fig 3. Kaplan–Meier survival analysis in GEICAM/9906 and METABRIC data sets based on the PAM50 proliferation score. Patients with (A) TNBC and (B) TNBC and BLBC treated with adjuvant chemotherapy in GEICAM/9906.

Fig 3. Kaplan–Meier survival analysis in GEICAM/9906 and METABRIC data sets based on the PAM50 proliferation score. Patients with (A) TNBC and (B) TNBC and BLBC treated with adjuvant chemotherapy in GEICAM/9906.
  • Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O2, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E

  • Br J Cancer. 2014 Oct 14;111(8):1532-41
Open Access button

2014-12-03

Fig 1. p19Arf deficiency significantly suppresses prostate tumorigenesis in Pten/Trp53 mice. (A) Actual sizes of representative tumors from anterior prostates (APs) of Wt, Ptenpc–/–; Trp53pc–/– double-mutant, and Ptenpc–/–; Trp53pc–/–; p19Arf–/– triple-mutant mice at 6 months of age.

Fig 1. p19Arf deficiency significantly suppresses prostate tumorigenesis in Pten/Trp53 mice. (A) Actual sizes of representative tumors from anterior prostates (APs) of Wt, Ptenpc–/–; Trp53pc–/– double-mutant, and Ptenpc–/–; Trp53pc–/–; p19Arf–/– triple-mutant mice at 6 months of age.
  • Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ, Chen Z

  • Mol Oncol. 2014 Oct;8(7):1355-64.

2014-12-04

Fig 4. Waterfall plot of best CNS response. Bars indicate the change from baseline in the size of CNS tumours, for every assessable patient with measurable CNS lesions at baseline (n=9). Red box indicates patients who had a partial response as their best CNS response. + symbols indicate patients still on treatment. *Radiation necrosis.

Fig 4. Waterfall plot of best CNS response. Bars indicate the change from baseline in the size of CNS tumours, for every assessable patient with measurable CNS lesions at baseline (n=9). Red box indicates patients who had a partial response as their best CNS response. + symbols indicate patients still on treatment. *Radiation necrosis.
  • Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.

  • Lancet Oncol. 2014 Sep;15(10):1119-28

2014-12-05

Fig 1. Sustained neutrophil engraftment after myeloablative double-unit CBT by infused viable CD34+ cell dose per kilogram of the dominant unit (n = 128).

Fig 1. Sustained neutrophil engraftment after myeloablative double-unit CBT by infused viable CD34+ cell dose per kilogram of the dominant unit (n = 128).
  • Purtill D, Smith K, Devlin S, Meagher R, Tonon J, Lubin M, Ponce DM, Giralt S, Kernan NA, Scaradavou A, Stevens CE, Barker JN

  • Blood. 2014 Nov 6;124(19):2905-12.

2014-12-08

Graphical Abstract.

Graphical Abstract.
  • Gao P, Postiglione MP, Krieger TG, Hernandez L, Wang C, Han Z, Streicher C, Papusheva E, Insolera R, Chugh K, Kodish O, Huang K, Simons BD, Luo L, Hippenmeyer S, Shi SH

  • Cell. 2014 Nov 6;159(4):775-88.

2014-12-09

Graphical abstract.

Graphical abstract.
  • Bucci V, Xavier JB

  • J Mol Biol. 2014 Nov 25;426(23):3907-3916.

2014-12-10

Fig 1. gE/AS01B, glycoprotein E/liposome-based adjuvant (50 µg MPL, 50 µg QS21); gE/AS01E, glycoprotein E/liposome-based adjuvant (25 µg MPL, 25 µg QS21); SAEs, serious adverse events. *Four subjects (2 in the gE/AS01E and 2 in the saline groups) with confirmed HZ were included in the safety analysis but were excluded from the immunogenicity analyses at month 15.

Fig 1. gE/AS01B, glycoprotein E/liposome-based adjuvant (50 µg MPL, 50 µg QS21); gE/AS01E, glycoprotein E/liposome-based adjuvant (25 µg MPL, 25 µg QS21); SAEs, serious adverse events. *Four subjects (2 in the gE/AS01E and 2 in the saline groups) with confirmed HZ were included in the safety analysis but were excluded from the immunogenicity analyses at month 15.
  • Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, El Idrissi M, Heineman TC, Berkowitz EM

  • Blood. 2014 Nov 6;124(19):2921-9.

2014-12-11

Fig 2. Cisplatin–DNA adduct formation and immunofluorescence: Visualization of cisplatin intrastrand DNA adducts in one patient's tumor tissue sample before and after HIPEC; the other two patients showed similar results.

Fig 2. Cisplatin–DNA adduct formation and immunofluorescence: Visualization of cisplatin intrastrand DNA adducts in one patient's tumor tissue sample before and after HIPEC; the other two patients showed similar results.
  • Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, Ruehs H, Keyver-Paik MD, Rudlowski C, Weber S, Kiefer N, Poelcher ML, Thiesler T, Rostamzadeh B, Mallmann M, Schaefer N, Permantier M, Latten S, Kalff J, Thomale J, Jaehde U, Kuhn WC

  • Int J Cancer. 2015 Feb 15;136(3):699-708.

2014-12-12

Graphical Abstract

Graphical Abstract
  • Karo JM, Schatz DG, Sun JC

  • Cell. 2014 Sep 25;159(1):94-107.

2014-12-15

Fig 1a. Waterfall plot, response of 32 human PDAC tumor xenografts to gemcitabine.

Fig 1a. Waterfall plot, response of 32 human PDAC tumor xenografts to gemcitabine.
  • Yu KH, Ricigliano M, Hidalgo M, Abou-Alfa GK, Lowery MA, Saltz LB, Crotty JF, Gary K, Cooper B, Lapidus R, Sadowska M, O'Reilly EM

  • Clin Cancer Res. 2014 Oct 15;20(20):5281-9.

2014-12-16

Fig 1a. Identification of gene expression subtypes in EEC.

Fig 1a. Identification of gene expression subtypes in EEC.
  • Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W

  • J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju245.

2014-12-17

Fig 1A. Smoking dysregulated genes in the small airway epithelium. Volcano plot, smoker vs nonsmoker small airway epithelium (n = 29 nonsmokers and n = 29 smokers) using all expressed (P call ≥10) probesets as input dataset.

Fig 1A. Smoking dysregulated genes in the small airway epithelium. Volcano plot, smoker vs nonsmoker small airway epithelium (n = 29 nonsmokers and n = 29 smokers) using all expressed (P call ≥10) probesets as input dataset.
  • Walters MS, De BP, Salit J, Buro-Auriemma LJ, Wilson T, Rogalski AM, Lief L, Hackett NR, Staudt MR, Tilley AE, Harvey BG, Kaner RJ, Mezey JG, Ashbridge B, Moore MA, Crystal RG

  • Respir Res. 2014 Sep 24;15(1):94.
Open Access button

2014-12-18

Fig 1. NRAS and PIK3CA mutations in ECD histiocytes and CD14+ cells from peripheral blood.

Fig 1. NRAS and PIK3CA mutations in ECD histiocytes and CD14+ cells from peripheral blood.
  • Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J

  • Blood. 2014 Nov 6;124(19):3016-9.
Open Access button

2014-12-19

Fig 1. SP MF CD34+ cells responded to the treatment of AZD1480 in a dose-dependent fashion, whereas normal CB CD34+ cells were less responsive to the effects of AZD1480.

Fig 1. SP MF CD34+ cells responded to the treatment of AZD1480 in a dose-dependent fashion, whereas normal CB CD34+ cells were less responsive to the effects of AZD1480.
  • Wang X, Ye F, Tripodi J, Hu CS, Qiu J, Najfeld V, Novak J, Li Y, Rampal R, Hoffman R

  • JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis

2014-12-22

Fig 3. Effects of AAVrh10.BevMab on angiogenesis of ovarian cancer. A2780 cells (5 × 106) were administered intraperitoneally into Balb/c nude mice. One day after tumor cell inoculation, mice were treated with 1011 gc AAVrh10. BevMab or, as controls, AAVrh10.αPA or PBS. On day 24, tumor nodules were collected. Frozen sections were stained with rat anti-mouse CD31 followed by goat anti-rat IgG conjugated with cy3. Nuclei were stained with DAPI. A. CD31 + tumors for PBS control, AAVrh.10αPA control and AAVrh.10BevMab. B. Quantification of blood vessel area. Data were obtained from n = 4 mice per group.

Fig 3. Effects of AAVrh10.BevMab on angiogenesis of ovarian cancer. A2780 cells (5 × 106) were administered intraperitoneally into Balb/c nude mice. One day after tumor cell inoculation, mice were treated with 1011 gc AAVrh10. BevMab or, as controls, AAVrh10.αPA or PBS. On day 24, tumor nodules were collected. Frozen sections were stained with rat anti-mouse CD31 followed by goat anti-rat IgG conjugated with cy3. Nuclei were stained with DAPI. A. CD31 + tumors for PBS control, AAVrh.10αPA control and AAVrh.10BevMab. B. Quantification of blood vessel area. Data were obtained from n = 4 mice per group.
  • Xie Y, Hicks MJ, Kaminsky SM, Moore MA, Crystal RG, Rafii A

  • Gynecol Oncol. 2014 Nov;135(2):325-32.

2014-12-23

Graphical Abstract.

Graphical Abstract.
  • Westholm JO, Miura P, Olson S, Shenker S, Joseph B, Sanfilippo P, Celniker SE, Graveley BR, Lai EC

  • Cell Rep. 2014 Dec 11;9(5):1966-1981.

2014-12-24

Fig 4. Impact of APOE and smoking status for working memory. The bar plot of the observed average post-treatment working memory outcomes is shown. The error bars represent the model-predicted 95% confidence intervals. Specific statistical contrasts were applied to test the APOE4 and smoking history interaction within patients treated with chemotherapy (contrast (a)), patients not treated with chemotherapy (contrast (b)), and controls (contrast (c).)

Fig 4. Impact of APOE and smoking status for working memory. The bar plot of the observed average post-treatment working memory outcomes is shown. The error bars represent the model-predicted 95% confidence intervals. Specific statistical contrasts were applied to test the APOE4 and smoking history interaction within patients treated with chemotherapy (contrast (a)), patients not treated with chemotherapy (contrast (b)), and controls (contrast (c).)
  • Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, Tsongalis GJ, Moore JH, Saykin AJ

  • Psychooncology. 2014 Dec;23(12):1382-90.

2014-12-26

Fig 6. Structural perturbations in the acceptor site of the GTP-Mg2+-pDNA complex.  The structures of the CthPnk-D38N-GTP-Mg2+-HODNA Michaelis complex (PDB code 4MDF; cyan) and the wild-type CthPnk-GTP-Mg2+-pDNA complex (green) were superimposed. The DNA ligands and selected side chains are shown as stick models in a stereo view highlighting changes in side chain position and orientation caused by the DNA 5′-phosphate. The blue line denotes the 4.8 Å displacement of the Glu48 Cα atom of the loop segment connecting two α helices that form the acceptor-binding site.

Fig 6. Structural perturbations in the acceptor site of the GTP-Mg2+-pDNA complex. The structures of the CthPnk-D38N-GTP-Mg2+-HODNA Michaelis complex (PDB code 4MDF; cyan) and the wild-type CthPnk-GTP-Mg2+-pDNA complex (green) were superimposed. The DNA ligands and selected side chains are shown as stick models in a stereo view highlighting changes in side chain position and orientation caused by the DNA 5′-phosphate. The blue line denotes the 4.8 Å displacement of the Glu48 Cα atom of the loop segment connecting two α helices that form the acceptor-binding site.
  • Das U, Wang LK, Smith P, Munir A, Shuman S

  • J Bacteriol. 2014 Dec 15;196(24):4285-92.

2014-12-29

Fig 1. Structure of BRAF and RAF1 fusions.

Fig 1. Structure of BRAF and RAF1 fusions.
  • Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, Ross JS, Basturk O, Balasubramanian S, Lipson D, Yelensky R, Pao W, Miller VA, Klimstra DS, Stephens PJ

  • Cancer Discov. 2014 Dec;4(12):1398-405.

2014-12-30

Fig 3. Unadjusted Kaplan-Meier curve for overall survival.

Fig 3. Unadjusted Kaplan-Meier curve for overall survival.
  • Salgado LR, Spratt DE, Riaz N, Romesser PB, Wolden S, Rao S, Chin C, Hong JC, Wong R, Lee NY

  • Am J Clin Oncol. 2014 Oct;37(5):492-7.

2014-12-31

Fig 1. Overall structure of FAN1-5′pG1/3′T4. (A) Cartoon representation. NTD, pink; CTD, light blue, dsDNA, yellow; flaps and 5′ phosphate spheres, red; and Ca2+, purple. The inset shows a line drawing of the DNA. (B) View looking down the vertical axis of (A). (C) The six different domains of FAN1 are colored according to the linear representation. WH, winged helix.

Fig 1. Overall structure of FAN1-5′pG1/3′T4. (A) Cartoon representation. NTD, pink; CTD, light blue, dsDNA, yellow; flaps and 5′ phosphate spheres, red; and Ca2+, purple. The inset shows a line drawing of the DNA. (B) View looking down the vertical axis of (A). (C) The six different domains of FAN1 are colored according to the linear representation. WH, winged helix.
  • Wang R, Persky NS, Yoo B, Ouerfelli O, Smogorzewska A, Elledge SJ, Pavletich NP

  • Science. 2014 Nov 28;346(6213):1127-30.